---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-057578"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2023-12-14T23:59:59+00:00"
generated_at: "2026-06-07T12:51:05.856721+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Roivant closes $7.1B sale of Telavant to Roche; retains 75% ownership prior to closing

## Summary
- Total upfront cash consideration of approximately $7.1 billion paid to Telavant equity holders.
- Roivant owned 75% of Telavant on an as-converted basis before the transaction closed.
- Additional $150 million cash milestone payable upon initiation of a Phase 3 ulcerative colitis trial.
- Telavant holds US and Japan rights to TL1A antibody RVT-3101 for IBD and Crohn's disease.

## SEC filing metadata
- accession: 0001140361-23-057578
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2023-12-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036123057578/0001140361-23-057578-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036123057578/ef20016626_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-057578
- JSON: https://secwatch.observer/filing/0001140361-23-057578.json
- Plain text: https://secwatch.observer/filing/0001140361-23-057578.txt

## Key facts
- M&A Transactions
  Roivant Sciences Ltd. completed a disposition involving Roche Holdings, Inc. for approximately $7.1 billion in cash (closed 2023-12-14).
  - Action: disposition
  - Counterparty: Roche Holdings, Inc.
  - Consideration: approximately $7.1 billion in cash
  - Closing: 2023-12-14
  source text: On December 14, 2023, pursuant to the Purchase Agreement, the Buyer completed the Transaction for total consideration of approximately $7.1 billion in cash at the closing of the Transaction (the “Closing”), paid or to be paid to all of Telavant’s equity holders, including holders of restricted stock units, on a pro rata basis relative to their ownership of Telavant prior to the Closing.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1635088/000114036123057578/0001140361-23-057578-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.